InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class m…
| Métrica | IFRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | -24677.9% | 57.4% | -24735.3% |
| Operating Margin | — | -34.4% | — |
| Net Margin | -155582.1% | -32.5% | -155549.6% |
| FCF Margin | -120793.8% | -12.6% | -120781.2% |
| ROE | -636.3% | -39.2% | -597.2% |
| ROA | -82.7% | -30.9% | -51.7% |
| Current Ratio | 4.13 | 2.73 | +1.40 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -82.6% | — |
| ✗Flujo de caja operativo positivo | −€35M | −€49M |
| ✗Rentabilidad sobre activos al alza | -82.6% | -60.6% |
| ✓Caja operativa/activos supera al ROA | -64.0% | ROA -82.6% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 4.13 | 5.06 |
| ✗Sin aumentar el nº de acciones | 67M | 59M |
| ✗Margen bruto al alza | -24677.9% | -1900.8% |
| ✗Rotación de activos al alza | 0.00 | 0.00 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -120793.8% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 88085.9% |
InflaRx N.V. cotiza a 1.32 USD y tiene una capitalización bursátil de $195M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud